导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.88% | 2434/4773 |
| 近一周 | -2.93% | 3394/5462 |
| 近一月 | -7.53% | 3858/5421 |
| 近一季 | -13.72% | 4068/5209 |
| 近半年 | -2.36% | 1873/4920 |
| 近一年 | 1.32% | 2360/4366 |
| 近两年 | 56.38% | 1298/2954 |
| 近三年 | 29.04% | 1089/2253 |
| 成立以来 | 68.55% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.79% 2483/4961 |
20.55% 1220/5312 |
- - |
- - |
| 2025 | 25.01% 1744/4813 |
-0.81% 2417/3635 |
-0.77% 3024/4076 |
29.67% 1210/4524 |
-2.06% 3078/4813 |
| 2024 | 12.45% 1243/3463 |
0.33% 995/2808 |
-3.28% 1335/3014 |
19.63% 821/3129 |
-3.14% 2268/3463 |
| 2023 | -15.19% 1641/2656 |
4.19% 1023/2280 |
-5.97% 1569/2385 |
-7.17% 1534/2515 |
-6.75% 1901/2655 |
| 2022 | -23.52% 1143/2207 |
-17.71% 1247/1919 |
8.56% 354/2016 |
-15.71% 1335/2113 |
1.56% 1222/2208 |
| 2021 | 0.86% 701/1822 |
-4.00% 844/1255 |
10.35% 471/1330 |
-7.42% 1050/1466 |
2.85% 507/1822 |
| 2020 | 49.26% 178/1250 |
-4.88% 387/1028 |
20.76% 260/1067 |
10.70% 521/1164 |
17.37% 127/1184 |
| 2019 | - - |
- - |
-2.41% 351/804 |
4.26% 208/850 |
10.41% 137/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 方正富邦深证100ETF联接C VS. 长安沪深300非周期A(740101) |